{"id":4869,"date":"2014-07-03T14:15:31","date_gmt":"2014-07-03T14:15:31","guid":{"rendered":"\/?p=4869"},"modified":"2014-07-03T14:16:14","modified_gmt":"2014-07-03T14:16:14","slug":"plandai-biotechnology-inc-otcmktsplpl-continues-its-climb","status":"publish","type":"post","link":"\/articles\/plandai-biotechnology-inc-otcmktsplpl-continues-its-climb\/","title":{"rendered":"Plandai Biotechnology, Inc. (OTCMKTS:PLPL) Continues Its Climb"},"content":{"rendered":"\n
Plandai Biotechnology, Inc. (OTCMKTS:PLPL<\/a>) had a slow month and a half since mid May, but now it’s on the rise again, with amazing dollar volumes and two digit jumps, the last of which took the ticker all the way up to $0.6.<\/div>\n
<\/div>\n
A jump of 22.45% for PLPL<\/a> <\/strong>seems unreasonable at this point in time, especially seeing how there has not been any developments on the company in more than a week. Still, this is happening right now, as investors are getting high on the hopes that the company is on the verge of releasing a piece of PR that will launch it sky-high again, in a manner reminiscent of PLPL<\/a>‘s <\/strong>ascent in February. <\/div>\n
<\/div>\n
Sadly for dedicated investors, even if PLPL<\/a> <\/strong>does pump out a piece of marijuana PR, the momentum it will gather will be short lived, for one simple reason. The company’s cannabis projects have not really had any progress, thus any news it can pump out on the matter is likely to be vague and boastful, but ultimately – inconsequential. The bottom line is – until PLPL<\/a> <\/strong>finds a way to conduct serious medical marijuana research, its hands are tied.<\/div>\n
<\/div>\n
Worse yet, even if the company does manage to enter a development stage for a medical marijuana product, OTC Markets traders should know better than to expect immediate results from PLPL<\/a><\/strong>. Pharmaceutical developments and tests before a product can be brought to the market usually take years, as well as an aggregate of finance that PLPL<\/a><\/strong> simply <\/strong>does not currently have available. The company’s latest quarterly report, for the period ended March March 31, 2014 showed:<\/div>\n
\n